- Jingtai Holdings (02228) saw a nearly 7% increase in early trading, with its stock price doubling since early August, currently at HKD 12.37.
- Jingtai Technology and Baicheng Pharmaceutical (301096.SZ) signed a cooperation agreement to utilize Jingtai's "AI + robotics" platform for new drug development, addressing unmet clinical needs in various disease areas.
- According to Guangfa Securities, Jingtai aims to be a neutral third-party service provider in AI-driven drug development, which may enhance its role as an industry infrastructure as AI integration deepens in drug discovery.
